```

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2283 Introduced in House (IH)]

<DOC>

116th CONGRESS
  1st Session
                                H. R. 2283

     To provide better care and outcomes for Americans living with 
 Alzheimer's disease and related dementias and their caregivers while 
 accelerating progress toward prevention strategies, disease modifying 
                  treatments, and, ultimately, a cure.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 10, 2019

 Ms. Sanchez (for herself, Mr. LaHood, Ms. Matsui, and Mrs. Rodgers of 
 Washington) introduced the following bill; which was referred to the 
 Committee on Energy and Commerce, and in addition to the Committee on 
   Ways and Means, for a period to be subsequently determined by the 
  Speaker, in each case for consideration of such provisions as fall 
           within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL

 
     To provide better care and outcomes for Americans living with 
 Alzheimer's disease and related dementias and their caregivers while 
 accelerating progress toward prevention strategies, disease modifying 
                  treatments, and, ultimately, a cure.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE; TABLE OF CONTENTS; FINDINGS.

    (a) Short Title.--This Act may be cited as the ``Concentrating on 
High-value Alzheimer's Needs to Get to an End Act of 2019'' or the 
``CHANGE Act of 2019''.
    (b) Table of Contents.--The table of contents of this Act is as 
follows:

Sec. 1. Short title; table of contents; findings.
Sec. 2. Cognitive impairment detection benefit in the Medicare annual 
                            wellness visit and initial preventive 
                            physical examination.
Sec. 3. Medicare quality payment program.
Sec. 4. Report to Congress on implementation of this Act.
Sec. 5. Study and report on regulatory and legislative changes or 
                            refinements that would accelerate 
                            Alzheimer's disease research progress.
    (c) Findings.--Congress finds as follows:
            (1) It is estimated that 5.8 million Americans are living 
        with Alzheimer's disease in 2019. This includes an estimated 
        5.6 million people age 65 and older and approximately 200,000 
        individuals under age 65 who have younger-onset Alzheimer's. By 
        2050, the number of people age 65 and older with Alzheimer's 
        dementia is projected to increase to 13.8 million Americans.
            (2) As many as half of the estimated 5,100,000 American 
        seniors with Alzheimer's disease and other dementias have never 
        received a diagnosis.
            (3) In 2019, it is estimated that Alzheimer's and related 
        dementias will have cost the Medicare and Medicaid programs 
        $195 billion. By 2050, it is estimated that these direct costs 
        will increase to as much as $1.1 trillion.
            (4) Alzheimer's exacts an emotional and physical toll on 
        caregivers, resulting in higher incidence of heart disease, 
        cancer, depression, and other health consequences.
            (5) Alzheimer's disease disproportionately impacts women 
        and people of color. Women are twice as likely to develop 
        Alzheimer's as they are breast cancer. African Americans are 
        about two times more likely than White Americans to have 
        Alzheimer's disease and other dementias. Latinos are about one 
        and one-half times more likely than White Americans to have 
        Alzheimer's disease and other dementias. According to the 
        Centers for Disease Control and Prevention, among people ages 
        65 and older, African Americans have the highest prevalence of 
        Alzheimer's disease and related dementias (13.8 percent), 
        followed by Hispanics (12.2 percent), and non-Hispanic Whites 
        (10.3 percent), American Indian and Alaska Natives (9.1 
        percent), and Asian and Pacific Islanders (8.4 percent). This 
        higher prevalence translates into a higher death rate: 
        Alzheimer's deaths increased 55 percent among all Americans 
        between 1999 and 2014, while the number was 107 percent for 
        Latinos and 99 percent for African Americans.
            (6) There are evidence-based, reliable, and NIH-identified 
        cognitive impairment detection tools available at the National 
        Institute on Aging's Alzheimer's and Dementia Resources for 
        Professionals website that must replace detection by direct 
        observation in the Medicare Annual visits and Welcome to 
        Medicare visits. The NIH-identified tools will allow for 
        appropriate follow-up instead of delaying diagnosis or impeding 
        opportunities for patients to access timely treatment options, 
        including clinical trial participation.
            (7) An early, documented diagnosis, communicated to the 
        patient and caregiver, enables early access to care planning 
        services and available medical and nonmedical treatments, and 
        optimizes patients' ability to build a care team, participate 
        in support services, and enroll in clinical trials.
            (8) African Americans represent 13 percent of the 
        population of the United States but only 5 percent of clinical 
        trial participants, and Latinos represent 17 percent of the 
        population of the United States but less than one percent of 
        clinical trial participants. Further, Latinos and African 
        Americans account for only 3.5 percent and 1.2 percent, 
        respectively, of principal investigators supported by the 
        National Institutes of Health funding, limiting this 
        perspective in research. Better recruitment and trial designs 
        are critical to addressing innovation in Alzheimer's generally, 
        including the underrepresentation of African Americans and 
        Latinos.
            (9) Inability to identify eligible patients at the earliest 
        stages of disease is a substantial impediment to efficient 
        research toward Alzheimer's disease prevention, treatment, and 
        cure.
            (10) Advancing treatment options to prevent, treat, or cure 
        Alzheimer's is an urgent national priority.
            (11) A paradigm shift to drive synergies between high-value 
        patient care, caregiver support, brain health promotion, and 
        research initiatives is our best hope for preventing, treating, 
        and curing Alzheimer's disease.

SEC. 2. COGNITIVE IMPAIRMENT DETECTION BENEFIT IN THE MEDICARE ANNUAL 
              WELLNESS VISIT AND INITIAL PREVENTIVE PHYSICAL 
              EXAMINATION.

    (a) Annual Wellness Visit.--
            (1) In general.--Section 1861(hhh)(2) of the Social 
        Security Act (42 U.S.C. 1395x(hhh)(2)) is amended--
                    (A) by striking subparagraph (D) and inserting the 
                following:
                    ``(D) Detection of any cognitive impairment or 
                progression of cognitive impairment that shall--
                            ``(i) be performed using a cognitive 
                        impairment detection tool identified by the 
                        National Institute on Aging as meeting its 
                        criteria for selecting instruments to detect 
                        cognitive impairment in the primary care 
                        setting, and other validated cognitive 
                        detection tools as the Secretary determines;
                            ``(ii) include documentation of the tool 
                        used for detecting cognitive impairment and 
                        results of the assessment in the patient's 
                        medical record; and
                            ``(iii) take into consideration the tool 
                        used, and results of, any previously performed 
                        cognitive impairment detection assessment.'';
                    (B) by redesignating subparagraph (I) as 
                subparagraph (J); and
                    (C) by inserting after subparagraph (H) the 
                following new subparagraph:
                    ``(I) Referral of patients with detected cognitive 
                impairment or potential cognitive decline to--
                            ``(i) appropriate Alzheimer's disease and 
                        dementia diagnostic services, including amyloid 
                        positron emission tomography, and other 
                        medically accepted diagnostic tests that the 
                        Secretary determines are safe and effective;
                            ``(ii) specialists and other clinicians 
                        with expertise in diagnosing or treating 
                        Alzheimer's disease and related dementias;
                            ``(iii) available community-based services, 
                        including patient and caregiver counseling and 
                        social support services; and
                            ``(iv) appropriate clinical trials.''.
            (2) Effective date.--The amendments made by paragraph (1) 
        shall apply to annual wellness visits furnished on or after 
        January 1, 2020.
    (b)  Initial Preventive Physical Examination.--
            (1) In general.--Section 1861(ww)(1) of the Social Security 
        Act (42 U.S.C. 1395x(ww)(1)) is amended by striking ``agreement 
        with the individual, and'' and inserting ``agreement with the 
        individual, detection of any cognitive impairment or 
        progression of cognitive impairment as described in 
        subparagraph (D) of subsection (hhh)(2) and referrals as 
        described in subparagraph (I) of such subsection, and''.
            (2) Effective date.--The amendments made by paragraph (1) 
        shall apply to initial preventive physical examinations 
        furnished on or after January 1, 2020.

SEC. 3. MEDICARE QUALITY PAYMENT PROGRAM.

    Not later than January 1, 2020, the Secretary of Health and Human 
Services shall implement Medicare policies under title XVIII of the 
Social Security Act, including quality measures and Medicare Advantage 
plan rating and risk adjustment mechanisms, that reflect the public 
health imperative of--
            (1) promoting healthy brain lifestyle choices;
            (2) identifying and responding to patient risk factors for 
        Alzheimer's disease and related dementias; and
            (3) incentivizing providers for--
                    (A) adequate and reliable cognitive impairment 
                detection in the primary care setting, that is 
                documented in the patient's electronic health record 
                and communicated to the patient;
                    (B) timely Alzheimer's disease diagnosis; and
                    (C) appropriate care planning services, including 
                identification of, and communication with patients and 
                caregivers about, the potential for clinical trial 
                participation.

SEC. 4. REPORT TO CONGRESS ON IMPLEMENTATION OF THIS ACT.

    Not later than 3 years after the date of the enactment of this Act, 
the Secretary of Health and Human Services shall submit a report to 
Congress on the implementation of the provisions of, and amendments 
made by, this Act, including--
            (1) the increased use of validated tools for detection of 
        cognitive impairment and Alzheimer's disease;
            (2) utilization of Alzheimer's disease diagnostic and care 
        planning services; and
            (3) outreach efforts in the primary care and patient 
        communities.

SEC. 5. STUDY AND REPORT ON REGULATORY AND LEGISLATIVE CHANGES OR 
              REFINEMENTS THAT WOULD ACCELERATE ALZHEIMER'S DISEASE 
              RESEARCH PROGRESS.

    (a) In General.--The Comptroller General of the United States (in 
this section referred to as the ``Comptroller General'') shall conduct 
a study on regulatory and legislative changes or refinements that would 
accelerate Alzheimer's disease research progress. In conducting such 
study, the Comptroller General shall consult with interested 
stakeholders, including industry leaders, researchers, clinical 
experts, patient advocacy groups, caregivers, patients, providers, and 
State leaders. Such study shall include an analysis of innovative 
public-private partnerships, innovative financing tools, incentives, 
and other mechanisms to enhance the quality of care for individuals 
diagnosed with Alzheimer's disease, reduce the emotional, financial, 
and physical burden on familial care partners, and accelerate 
development of preventative, curative, and disease-modifying therapies.
    (b) Report.--Not later than 1 year after the date of the enactment 
of this Act, the Comptroller General shall submit to Congress a report 
containing the results of the study conducted under subsection (a), 
together with recommendations for such legislation and administrative 
action as the Comptroller General determines appropriate.
                                 <all>
```